Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. The company is headquartered in Zhongshan, Guangdong and currently employs 3,529 full-time employees. The company went IPO on 2020-04-24. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The firm's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
09926.HK stock price ended at $105.3 on Vendredi, after rising 1.54%
On the latest trading day Feb 13, 2026, the stock price of 09926.HK rose by 1.54%, climbing from $102.20 to $105.30. Throughout the session, the stock experienced a volatility of 3.43%, with prices fluctuating between a daily low of $102.10 and a high of $105.60. Alongside this price increase, trading volume also rose by 129.5K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 2.9M shares were traded, amounting to a market value of approximately $96.9B.
Signaux Techniques de 09926.HK
Résumé des Signaux Techniques
Acheter des signaux 1
Signaux neutres 2
Signaux de vente 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
09926.HK présente actuellement 1 signaux d'achat et 4 signaux de vente. L'action est en tendance haussière depuis 12:00 AM, avec une variation totale du prix de 1.54% pendant cette période. En général, les indicateurs techniques indiquent une tendance Sell à moyen terme.
Signaux haussiers/baissiers pour 09926.HK
Nous analysons les indicateurs clés comme les moyennes mobiles, le RSI, le MACD et le volume de transactions pour générer des signaux haussiers et baissiers pour 09926.HK, vous aidant à prendre des décisions d'investissement éclairées.